Literature DB >> 2820300

Activity of LY146032 compared with that of methicillin, cefazolin, cefamandole, cefuroxime, ciprofloxacin, and vancomycin against staphylococci as determined by kill-kinetic studies.

C W Stratton, C Liu, L S Weeks.   

Abstract

Kill-kinetic methods were used to provide data on the bactericidal activity of subinhibitory (0.5x MIC), inhibitory (1x MIC), and suprainhibitory (4x MIC) concentrations of LY146032 against methicillin-susceptible and -resistant Staphylococcus aureus and Staphylococcus epidermidis. These bactericidal activities were compared with those of methicillin, cefazolin, cefamandole, cefuroxime, ciprofloxacin, and vancomycin. LY146032 was among the most active of the antistaphylococcal agents tested, as determined by broth microdilution methods, with all strains being inhibited at concentrations of less than or equal to 1 microgram/ml. Time kill-kinetic studies demonstrated that at 4x MIC, LY146032 was rapidly bactericidal against all strains of staphylococci. Our data show that LY146032 has significant bactericidal activity against staphylococci in comparison with other antistaphylococcal agents. Further evaluation of LY146032 against serious staphylococcal infections is warranted.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2820300      PMCID: PMC174905          DOI: 10.1128/AAC.31.8.1210

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  18 in total

1.  In vitro activity of LY146032, a new lipopeptide antibiotic, against gram-positive cocci.

Authors:  L Verbist
Journal:  Antimicrob Agents Chemother       Date:  1987-02       Impact factor: 5.191

Review 2.  Staphylococcus aureus. The persistent pathogen (first of two parts).

Authors:  J N Sheagren
Journal:  N Engl J Med       Date:  1984-05-24       Impact factor: 91.245

Review 3.  Staphylococcus epidermidis infections.

Authors:  F D Lowy; S M Hammer
Journal:  Ann Intern Med       Date:  1983-12       Impact factor: 25.391

4.  Staphylococcal bacteremia: current patterns in nonuniversity hospitals.

Authors:  C S Bryan; B Kirkhart; E R Brenner
Journal:  South Med J       Date:  1984-06       Impact factor: 0.954

5.  In vitro activity and mechanism of action of A21978C1, a novel cyclic lipopeptide antibiotic.

Authors:  G M Eliopoulos; C Thauvin; B Gerson; R C Moellering
Journal:  Antimicrob Agents Chemother       Date:  1985-03       Impact factor: 5.191

6.  Complications associated with Staphylococcus aureus bacteremia.

Authors:  H Libman; R D Arbeit
Journal:  Arch Intern Med       Date:  1984-03

7.  Therapy of staphylococcal infections with cefamandole or vancomycin alone or with a combination of cefamandole and tobramycin.

Authors:  L Coppens; B Hanson; J Klastersky
Journal:  Antimicrob Agents Chemother       Date:  1983-01       Impact factor: 5.191

8.  Successful use of broth microdilution in susceptibility tests for methicillin-resistant (heteroresistant) staphylococci.

Authors:  C Thornsberry; L K McDougal
Journal:  J Clin Microbiol       Date:  1983-11       Impact factor: 5.948

9.  Mechanisms of resistance to beta-lactam antibiotics in strains of Staphylococcus aureus.

Authors:  L D Sabath
Journal:  Ann Intern Med       Date:  1982-09       Impact factor: 25.391

10.  Cross-resistance between methicillin and cephalosporins for staphylococci: a general assumption not true for cefamandole.

Authors:  R F Frongillo; P Bianchi; A Moretti; M B Pasticci; S Ripa; S Pauluzzi
Journal:  Antimicrob Agents Chemother       Date:  1984-05       Impact factor: 5.191

View more
  15 in total

1.  Effect of subinhibitory concentrations of cefamandole and cefuroxime on adherence of Staphylococcus aureus and Staphylococcus epidermidis to polystyrene culture plates.

Authors:  H Carsenti-Etesse; J Durant; E Bernard; V Mondain; J Entenza; P Dellamonica
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1992-08       Impact factor: 3.267

2.  Levels of vancomycin in the cerebral interstitial fluid after severe head injury.

Authors:  Anselmo Caricato; Mariano Pennisi; Aldo Mancino; Gianluca Vigna; Claudio Sandroni; Andrea Arcangeli; Massimo Antonelli
Journal:  Intensive Care Med       Date:  2006-01-24       Impact factor: 17.440

3.  Cerebrospinal fluid penetration and pharmacokinetics of vancomycin administered by continuous infusion to mechanically ventilated patients in an intensive care unit.

Authors:  J Albanèse; M Léone; B Bruguerolle; M L Ayem; B Lacarelle; C Martin
Journal:  Antimicrob Agents Chemother       Date:  2000-05       Impact factor: 5.191

4.  Pharmacokinetics of Cefuroxime in Synovial Fluid.

Authors:  R Schwameis; S Syré; D Marhofer; A Appelt; D Burau; K Sarahrudi; C Kloft; M Zeitlinger
Journal:  Antimicrob Agents Chemother       Date:  2017-09-22       Impact factor: 5.191

5.  Influence of daptomycin on staphylococcal abscesses and experimental tobramycin nephrotoxicity.

Authors:  C A Wood; H C Finkbeiner; S J Kohlhepp; P W Kohnen; D N Gilbert
Journal:  Antimicrob Agents Chemother       Date:  1989-08       Impact factor: 5.191

6.  Penetration of vancomycin into mediastinal and cardiac tissues in humans.

Authors:  C Martin; M Alaya; M N Mallet; X Viviand; K Ennabli; R Said; P De Micco
Journal:  Antimicrob Agents Chemother       Date:  1994-02       Impact factor: 5.191

7.  Inoculum effect on growth-delay time of oxacillin-resistant strains of Staphylococcus aureus and Staphylococcus epidermidis exposed to cefamandole, cefazolin, and cefuroxime.

Authors:  E Yourassowsky; M P van der Linden; F Crokaert
Journal:  Antimicrob Agents Chemother       Date:  1990-04       Impact factor: 5.191

8.  Role of tolerance in treatment and prophylaxis of experimental Staphylococcus aureus endocarditis with vancomycin, teicoplanin, and daptomycin.

Authors:  G P Voorn; J Kuyvenhoven; W H Goessens; W C Schmal-Bauer; P H Broeders; J Thompson; M F Michel
Journal:  Antimicrob Agents Chemother       Date:  1994-03       Impact factor: 5.191

9.  In vitro pharmacodynamic effects of concentration, pH, and growth phase on serum bactericidal activities of daptomycin and vancomycin.

Authors:  K C Lamp; M J Rybak; E M Bailey; G W Kaatz
Journal:  Antimicrob Agents Chemother       Date:  1992-12       Impact factor: 5.191

10.  Penetration of ceftriaxone (1 or 2 grams intravenously) into mediastinal and cardiac tissues in humans.

Authors:  C Martin; X Viviand; M Alaya; F Lokiec; K Ennabli; R Said; M Pecking
Journal:  Antimicrob Agents Chemother       Date:  1996-03       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.